Prevention of muscle disuse atrophy by MG132 proteasome inhibitor

Muscle and Nerve

Volumn 43, Issue 5, 2011, Pages 708-715

  Jamart, Cecile ^a   Raymackers, Jean marc ^a   An, Gang Li ^a   Deldicque, Louise ^a   Francaux, Marc ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Chymotrypsin like activity; Hindlimb unloading; Mafbx; Murf 1; Usp28

Indexed keywords

ATROGIN 1; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BETA1 PROTEASOME; BETA2 PROTEASOME; BETA5 PROTEASOME; BINDING PROTEIN; MESSENGER RNA; MUSCLE RING FINGER 1 PROTEIN; PEPTIDASE; PROTEASOME; PROTEIN KINASE B; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHRL1; UBIQUITIN BINDING PROTEASE 45; UBIQUITIN PROTEIN LIGASE E3; UBIQUITIN PROTEIN LIGASE E3 ALPHA; UBIQUITIN PROTEIN LIGASE NEDD4; UBIQUITIN SPECIFIC PEPTIDASE 19; UBIQUITIN SPECIFIC PEPTIDASE 28; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; GASTROCNEMIUS MUSCLE; GENE EXPRESSION REGULATION; GENE REPRESSION; MALE; MOUSE; MUSCLE ATROPHY; MUSCLE DISUSE ATROPHY; MUSCLE MASS; MUSCLE TONE; NONHUMAN; PRIORITY JOURNAL; PROTEINASE INHIBITION; WEIGHT BEARING;

EID: 79955550020     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21949     Document Type: Article

References (38)

1. Lecker SH, Solomon V, Mitch WE, Goldberg AL. Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. J Nutr 1999;129(suppl):227S-237S.
2. Yimlamai T, Dodd SL, Borst SE, Park S. Clenbuterol induces musclespecific attenuation of atrophy through effects on the ubiquitin-proteasome pathway. J Appl Physiol 2005;99:71-80.
3. Reid MB. Response of the ubiquitin-proteasome pathway to changes in muscle activity. Am J Physiol Regul Integr Comp Physiol 2005;288: R1423-R1431.
4. Taillandier D, Combaret L, Pouch MN, Samuels SE, Bechet D, Attaix D. The role of ubiquitin-proteasome-dependent proteolysis in the remodelling of skeletal muscle. Proc Nutr Soc 2004;63:357-361.
5. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001;294:1704-1708.
6. Baptista IL, Leal ML, Artioli GG, Aoki MS, Fiamoncini J, Turri AO, et al. Leucine attenuates skeletal muscle wasting via inhibition of ubiquitin ligases. Muscle Nerve 2010;41:800-808.
7. Dupont-Versteegden EE, Fluckey JD, Knox M, Gaddy D, Peterson CA. Effect of flywheel-based resistance exercise on processes contributing to muscle atrophy during unloading in adult rats. J Appl Physiol 2006;101:202-212.
8. Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001;8:739-758.
9. Combaret L, Adegoke OA, Bedard N, Baracos V, Attaix D, Wing SS. USP19 is a ubiquitin-specific protease regulated in rat skeletal muscle during catabolic states. Am J Physiol Endocrinol Metab 2005;288: E693-E700.
10. Tawa NE Jr, Odessey R, Goldberg AL. Inhibitors of the proteasome reduce the accelerated proteolysis in atrophying rat skeletal muscles. J Clin Invest 1997;100:197-203.
11. Kadlcikova J, Holecek M, Safranek R, Tilser I, Kessler BM. Effects of proteasome inhibitors MG132, ZL3VS and AdaAhx3L3VS on protein metabolism in septic rats. Int J Exp Pathol 2004;85:365-371.
12. Bonuccelli G, Sotgia F, Schubert W, Park DS, Frank PG, Woodman SE, et al. Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. Am J Pathol 2003;163:1663-1675.
13. Safranek R, Ishibashi N, Oka Y, Ozasa H, Shirouzu K, Holecek M. Modulation of inflammatory response in sepsis by proteasome inhibition. Int J Exp Pathol 2006;87:369-372.
14. Supinski GS, Vanags J, Callahan LA. Effect of proteasome inhibitors on endotoxin-induced diaphragm dysfunction. Am J Physiol Lung Cell Mol Physiol 2009;296:L994-L1001.
15. Krawiec BJ, Frost RA, Vary TC, Jefferson LS, Lang CH. Hindlimb casting decreases muscle mass in part by proteasome-dependent proteolysis but independent of protein synthesis. Am J Physiol Endocrinol Metab 2005;289:E969-E980.
16. Beehler BC, Sleph PG, Benmassaoud L, Grover GJ. Reduction of skeletal muscle atrophy by a proteasome inhibitor in a rat model of denervation. Exp Biol Med (Maywood) 2006;231:335-341.
17. Deldicque L, Theisen D, Bertrand L, Hespel P, Hue L, Francaux M. Creatine enhances differentiation of myogenic C2C12 cells by activating both p38 and Akt/PKB pathways. Am J Physiol Cell Physiol 2007; 293:C1263-1271.
18. Chopard A, Hillock S, Jasmin BJ. Molecular events and signalling pathways involved in skeletal muscle disuse-induced atrophy and the impact of countermeasures. J Cell Mol Med 2009;13:3032-3050.
19. Ferreira R, Vitorino R, Neuparth MJ, Appell HJ, Duarte JA, Amado F. Proteolysis activation and proteome alterations in murine skeletalmuscle submitted to 1 week of hindlimb suspension. Eur J Appl Physiol 2009;107:553-563.
20. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002;20:4420-4427.
21. Holecek M, Muthny T, Kovarik M, Sispera L. Proteasome inhibitor MG-132 enhances whole-body protein turnover in rat. Biochem Biophys Res Commun 2006;345:38-42.
22. Koncarevic A, Jackman RW, Kandarian SC. The ubiquitin-protein ligase Nedd4 targets Notch1 in skeletal muscle and distinguishes the subset of atrophies caused by reduced muscle tension. FASEB J 2007;21:427-437.
23. Wing SS. Control of ubiquitination in skeletal muscle wasting. Int J Biochem Cell Biol 2005;37:2075-2087.
24. Zhang P, Chen X, Fan M. Signaling mechanisms involved in disuse muscle atrophy. Med Hypotheses 2007;69:310-321.
25. Berthon P, Duguez S, Favier FB, Amirouche A, Feasson L, Vico L, et al. Regulation of ubiquitin-proteasome system, caspase enzyme activities, and extracellular proteinases in rat soleus muscle in response to unloading. Pflugers Arch 2007;454:625-633.
26. Farout L, Lamare MC, Cardozo C, Harrisson M, Briand Y, Briand M. Distribution of proteasomes and of the five proteolytic activities in rat tissues. Arch Biochem Biophys 2000;374:207-212.
27. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002; 82:373-428.
28. Lee DH, Goldberg AL. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol 1998;8:397-403.
29. Ferrington DA, Husom AD, Thompson LV. Altered proteasome structure, function, and oxidation in aged muscle. FASEB J 2005;19: 644-646.
30. Stohwasser R, Salzmann U, Giesebrecht J, Kloetzel PM, Holzhutter HG. Kinetic evidences for facilitation of peptide channelling by the proteasome activator PA28. Eur J Biochem 2000;267:6221-6230.
31. Rechsteiner M, Hill CP. Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors. Trends Cell Biol 2005;15:27-33.
32. Attaix D, Taillandier D, Combaret L, Ralliere C, Larbaud D, Aurousseau E, et al. Expression of subunits of the 19S complex and of the PA28 activator in rat skeletal muscle. Mol Biol Rep 1997;24:95-98.
33. Ustrell V, Pratt G, Gorbea C, Rechsteiner M. Purification and assay of proteasome activator PA200. Methods Enzymol 2005;398:321-329.
34. Zong C, Gomes AV, Drews O, Li X, Young GW, Berhane B, et al. Regulation of murine cardiac 20S proteasomes: role of associating partners. Circ Res 2006;99:372-380.
35. Myung J, Kim KB, Crews CM. The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev 2001;21:245-273.
36. Kupperman E, Lee EC, Cao Y, Bannerman B, Fitzgerald M, Berger A, et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 2010;70:3853.
37. Attar EC, De Angelo DJ, Supko JG, D'Amato F, Zahrieh D, Sirulnik A, et al. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res 2008;14:1446-1454.
38. Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ. Proteasome inhibition measurements: clinical application. Clin Chem 2000;46:673-683. 716